Personal and Home Care Products
CIRS Group
Chemicals
Cosmetic
Food
Medical Devices
Agrochemicals
C&K Testing
Carbon Neutrality
Search

SCCS Issued Final Opinion on the Safety of Benzyl Salicylate

from CIRS by

On November 6, 2023, the Scientific Committee on Consumer Safety (SCCS) of the European Union issued final opinion (SCCS/1656/23) on Benzyl salicylate. The preliminary opinion on the safety of Benzyl salicylate in cosmetics was released on June 13, 2023.

The SCCS concludes the following:

(1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of Benzyl Salicylate, does the SCCS consider Benzyl Salicylate safe when used up to the maximum concentrations provided in the dossier submission by the Benzyl Salicylate Consortium?

Based on the assessment of data provided and taking under consideration the concerns related to potential endocrine disrupting properties, the SCCS considers Benzyl Salicylate safe when used up to the maximum concentrations as provided in Table 1 of this Opinion.

(2) Alternatively, what is according to the SCCS the maximum concentration considered safe for use of Benzyl Salicylate in cosmetic products?

/

(3) Does the SCCS have any further scientific concerns with regard to the use of Benzyl Salicylate in cosmetic products?

The available data on Benzyl Salicylate provide some indications for an endocrine mode of action, but there is no evidence to suggest that this results in endocrine effects. The SCCS mandates do not address environmental aspects. Therefore, this assessment did not cover the safety of Benzyl Salicylate for the environment.

If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.

Further Information

SCCS/1656/23

  

We have launched a LinkedIn newsletter to keep you up to date on the latest developments across the chemical industry including food and FCMs and personal and home care.

Contact Us
+353 1 477 3710 (EU)
+44 20 3239 9430 (UK)
+1 703 520 1420 (USA)
+86 571 8720 6574 (CN)
+82 2 6347 8816 (KR)